Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q3 FY24 Earnings Presentation
25 slides from Dishman Carbogen Amcis's earnings presentation, Feb 14, 2024
Slide 1: Exchange filing cover letter
14th February, 2024 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code
Slide 2: Investor Presentation Quarter ended December 31st, 2023
Investor Presentation Quarter ended December 31 st , 2023
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
DISHMAN IN A NUTSHELL 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIs in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
PAST PERFORMANCE AT A GLANCE Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 24,129 4,087 21,407 5,519 20,586 20,436 19,120 4,976 3,374 3,260 3,902 4,142 2,538 2,744 26.8% 24.3% 18.2% 17.2% 14.3% FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22^ FY23^ FY19 FY2
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q3 FY24 Result Highlights
Q3 FY24 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA* (₹ mn) & EBITDA MARGIN* 6,398 6,511 1,189 1,149 18.0% 18.3% Q3FY23 Q3FY24 Q3FY23^ Q3FY24^ CASH PAT* (₹ mn) & CASH EPS* (₹) 5.7 5.4 889 851 Q3FY23 Q3FY24 Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PAT = Adj
Slide 9: 9M FY24 Result Highlights
9M FY24 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA* (₹ mn) & EBITDA MARGIN* 17,944 19,611 3,090 2,876 16.0% 15.8% 9MFY23 9MFY24 9MFY23^ 9MFY24^ CASH PAT* (₹ mn) & CASH EPS*(₹) 2,230 2,223 14.2 14.2 9MFY23 9MFY24 Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PA
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q3 FY24 Q3 FY23 YoY % 9M FY24 9M FY23 YoY % Income from Operations (Net) 6,510.9 6,397.9 1.8% 19,610.6 17,943.6 9.3% COGS 1,181.2 788.1 49.9% 4,157.8 3,320.1 25.2% Employee Expenses 3,092.0 2,702.3 14.4% 8,873.9 7,799.4 13.8% Other Expenses* 1,812.0 1,75
Slide 11: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenue (₹ mn) Q3 FY24 Q3 FY23 YoY % 9M FY24 9M FY23 YoY % CARBOGEN AMCIS - Contract Research & 5,058.1 4,623.8 9.4% 15,039.5 12,641.7 19.0% Manufacturing Services1 CARBOGEN AMCIS- Cholesterol & Vit D 610.0 825.1 -26.1% 2,409.3 2,103.0 14.6% Analogues2 DCAL India - NCE APIs
Slide 12: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q3 FY24 Total Operating Revenue – 9M FY24 CARBOGEN AMCIS - Contract Research & Manufacturing Services 8.5% 6.6% 4.4% 12.3% 4.4% 9.4% CARBOGEN AMCIS - Cholesterol & Vit D Analogues DCAL India - NCE APIs & Intermediates 77.7% 76.7% DCAL India - Quats & Generi
Slide 13: Margin Analysis
MARGIN ANALYSIS EBITDA Margin %* Q3 FY24 Q3 FY23 9M FY24 9M FY23 CARBOGEN AMCIS - Contract Research & 19.9% 22.3% 18.3% 18.8% Manufacturing Services1# CARBOGEN AMCIS- Cholesterol & Vit D 16.6% 17.1% 15.0% 18.1% Analogues2 DCAL India - NCE APIs & Intermediates3 11.3% - - 0.2% DCAL India - Quats & Gen
Slide 14: Q3 & 9M FY24 Result Highlights
Q3 & 9M FY24 RESULT HIGHLIGHTS Net Revenue at Rs 6,510.9 mn in Q3 FY24 up slightly by 1.8% YoY due to increase in revenue in Carbogen Amcis - CRAMS. Carbogen Amcis – CRAMS revenue increased by 9.4% YoY in Q3 FY24 primarily due to increase in revenues of development revenues. Carbogen Amcis – Cholest
Slide 15: Company Overview
COMPANY OVERVIEW
Slide 16: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 17: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 18: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: Superior Chemistry Skills & Capabilities USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA 28 dedicated R&D labs with multiple shift R&D CARBOGEN AMCIS BV., Veenendaal, The CARBOGEN AMCIS operations, including HIPO labs (Sha
Slide 19: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 20: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES ▪ Focus is on supporting the development process from bench to market ▪ Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 21: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 22: Industry Overview
INDUSTRY OVERVIEW
Slide 23: Expected Global Spending by Therapy Areas in 2027
EXPECTED GLOBAL SPENDING BY THERAPY AREAS IN 2027 Oncology & Obesity expected to lead growth 5-Yr CAGR 2023-2027 Oncology 377 13-16% Immunology 177 3-6% Diabetes 168 3-6% Top 20 Therapy Areas (US$ bn) - 2027 Cardiovascular 126 1-4% Respiratory 92 3-6% CNS 81 2-5% Infectious diseases 74 2-5% GU sexua
Slide 24: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent about 43% of global spending in 2027 and 56% of total spending in developed markets 56% 49% 47% 43% 43% 40% 39% 36% 32% 27% 28% 24% 16% 16% 12% 10% 2012 2017 2022 2027 Pharmerging Other Developed Global 10 Developed Source: IQVIA In
Slide 25: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Dishman Carbogen Amcis Ltd Global CFO Dishman Corporate House Email: harshil.dalal@dishmangroup.com Iscon-Bopal Road, Ambli Ahmedabad - 380058 Gujarat, Mr. Binay Sarda India Ernst & Young LLP www.imdcal.com P: +91 9920893764 Email: binay.sarda@in.ey.com
Dishman Carbogen Amcis — Q3 FY24 Earnings Presentation on 6ix